Alzamend Neuro reports early brain study data for AL001 compound Apr 7, 2026 08:07AM
Alzamend Neuro reports AL001 meets bioequivalence in phase II trial Mar 26, 2026 08:02AM
Alzamend Neuro starts phase II trial of AL001 for bipolar disorder Mar 16, 2026 08:02AM
Alzamend Neuro completes Phase II clinical trial of AL001 lithium therapy Nov 19, 2025 08:01AM
Alzamend Neuro (ALZN) Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital May 29, 2025 08:04AM


May 19, 2025 08:03AM Alzamend Neuro (ALZN) Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study
May 8, 2025 08:01AM Alzamend Neuro (ALZN) Announces 1:9 Reverse Share Split
Mar 27, 2025 04:35PM Alzamend Neuro (ALZN) Files for 75.78M Share Offering by Selling Stockholders
Mar 4, 2025 08:11AM Alzamend Neuro (ALZN) Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Feb 19, 2025 08:04AM Alzamend Neuro (ALZN) Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Nov 19, 2024 08:02AM Alzamend Neuro (ALZN) Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Oct 16, 2024 08:06AM Alzamend Neuro (ALZN) Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Oct 15, 2024 08:04AM Alzamend Neuro (ALZN) Regains Compliance with Nasdaq Listing Standards
Aug 26, 2024 08:04AM Alzamend Neuro (ALZN) Issues Letter to Stockholders
Aug 19, 2024 10:03AM Alzamend Neuro (ALZN) Climbs 525%
Aug 19, 2024 08:06AM Alzamend Neuro (ALZN) Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumati
Aug 12, 2024 08:03AM Alzamend Neuro (ALZN) Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001
Aug 5, 2024 09:10AM Alzamend Neuro (ALZN) Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s D
Jul 31, 2024 08:00AM Alzamend Neuro (ALZN) Regains Nasdaq Compliance
Jul 12, 2024 08:00AM Alzamend Neuro (ALZN) Announces 1:10 Reverse Share Split
Jun 26, 2024 04:48PM Alzamend Neuro (ALZN) Files for 125M Share Offering by Selling Stockholders